# Russell Hirsch

> Russell Hirsch is a seed investor at Prospect Venture Partners backing Health Care and Software. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Prospect Venture Partners](https://shizune.co/investors/profile/prospect-venture-partners)
- Location: Atlantic City, United States
- Total investments: 5
- Last investment: Jun 2022
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/russell-hirsch-8b0955b
- X (Twitter): http://twitter.com/russellhirsch
- Website: https://www.prospectventurepartners.com

Russell Hirsch is a seed investor at Prospect Venture Partners in Atlantic City focused on Health Care and Software. Russell is a Managing Director of Prospect Venture Partners. Russell co-founded Prospect Venture Partners II and III, as dedicated life science funds with over $1 billion in capital under management. Prior to establishing Prospect Venture Partners II and III, Russell was a member of the Health Care Technology Group at Mayfield. He joined Mayfieldin 1992, served as a Venture Partner from 1993 to 1994 and as a General Partner from 1995-2000. Russell played a key role in Mayfield's investment activities in the biotechnology and medical device sectors. As an Associate, he participated actively in the incubation of Millennium Pharmaceuticals and as a General Partner he was responsible for the incubation of Intuitive Surgical Devices both of which are now publicly traded. (NASDAQ: MLNM), (NASDAQ:ISRG).Prior to Mayfield, Russell was at the University of California San Francisco from 1984-1992 where he was engaged in biomedical research. His work, published in a variety of respected journals, focused on important aspects of hepatitis B viral replication. His descriptions of the reverse transcription and packaging functions of polymerase gene products merited publication in Nature.Russell serves or has served on the Board of Directors of Intuitive Surgical (NASDAQ: ISRG), Hansen Medical (NASDAQ: HNSN), Opus Medical (NASDAQ: ARTC), Orquest (NASDAQ: JNJ), AVEO Pharmaceuticals, Visiogen, Baxano, Dfine, Allux Medical, SentreHEART, Portola Pharmaceuticals and several other privately-held companies. Russell serves as the Vice Chairman of the BOD of Interplast and on the Genetics Advisory Council of the Harvard Medical School-Partners Healthcare Center for Genetics and Genomics.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 60% |
| Software | 2 | 40% |
| SaaS | 1 | 20% |
| Social | 1 | 20% |
| Content | 1 | 20% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 60% |
| Pre-Seed | 1 | 20% |
| Venture - Series Unknown | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Sholder | Sholder, short for Spaceholder™, is a new standard in non-clinical mental & emotional health, powered by compassionate, skilled people from communities like yours. We provide high-affinity, one-to-one emotional support for employees in industries with heavy emotional demand and high burnout rates. |  | Pre-Seed | Jun 30, 2022 |  |
| Sholder | Sholder, short for Spaceholder™, is a new standard in non-clinical mental & emotional health, powered by compassionate, skilled people from communities like yours. We provide high-affinity, one-to-one emotional support for employees in industries with heavy emotional demand and high burnout rates. |  | Seed | Jun 30, 2022 |  |
| datma | datma is a technology begins with hyperefficient data storage and aggregation solutions for genomic imaging, and other healthcare datasets. We couple this with best-in-class, fully customizable data visualization to ensure clinicians and researchers get the data and insights they need exactly when and how they need them. Findings that areindividually rare may be collectively common. dātma’s solutions for secure data federation ensure that healthcare data stay securely in the data owner’s tenancy while facilitating networked analysis and discovery. | $4M | Venture - Series Unknown | Jun 15, 2022 |  |
| Enwoven | Enwoven empowers organizations to combine important assets and context together in the form of dynamic narratives and flexible knowledge bases. Companies create valuable ideas, thoughts and insights that get lost everyday.We work with brands like the NY Times, Coca-Cola, Reebok, Campbell's, Avis, and Procter & Gamble to help themdocument brand history, marketing campaigns, innovation, important initiatives, company culture and much more. |  | Seed | Nov 04, 2015 |  |
| Glooko | Glooko is the universal diabetes platform that provides insights to improve outcomes for people with diabetes (PWDs) and their care teams. Glooko connects to the world’s most popular diabetes devices, major fitness and activity trackers and supplies personalized, timely patient information such as glucose level, food, insulin, medications, bloodpressure, diet and weight data. Trusted by the world’s leaders in diabetes care, we are in over 7,000 clinical locations and used by over 1.5 million PWDs in 23 countries across 15 languages. Learn more by visiting www.glooko.com. | $1M | Seed | Nov 10, 2011 |  |

5 of 5 investments shown.

## Co-investors
- [The Associated Press](https://shizune.co/investors/profile/associated-press) — VC Fund, 1 deal together
- [Matter](https://shizune.co/investors/profile/matter-ventures) — VC Fund, 1 deal together
- [The New York Times](https://shizune.co/investors/profile/newyorktimes) — VC Fund, 1 deal together
- [Prota Ventures](https://shizune.co/investors/profile/prota-ventures) — VC Fund, 1 deal together
- [Silverback Holdings](https://shizune.co/investors/profile/silverback-holdings) — VC Fund, 1 deal together
- [Social Capital](https://shizune.co/investors/profile/social-capital) — VC Fund, 1 deal together

## About Prospect Venture Partners

VC Fund · Palo Alto, United States

Prospect Venture Partners is a venture capital firm with over $1B of capital under management. The firm is dedicated to investing in outstanding biopharmaceutical and medical device companies. Prospect targets commercially attractive biomedical enterprises with outstanding entrepreneurial management teams, proprietary products, and innovativetechnologies with the potential for significant investment returns. The firm invests in companies with a wide variety of development and financing requirements including new company incubations, first and second venture financing rounds, and later stage private and public companies with proven business models requiring expansion capital.

3 contacts available at Prospect Venture Partners.

| Name | Title | Profile |
| --- | --- | --- |
| David Schnell | Managing Director | https://shizune.co/investors/profile/david-schnell |
| Russell Hirsch | Managing Director | https://shizune.co/investors/profile/russell-hirsch |
| Russell Hirsch | Managing Director | https://shizune.co/investors/profile/russell-hirsch-8da2 |

## Similar investors

### Similar industry
- [Goodwater Capital](https://shizune.co/investors/profile/goodwater-capital) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [SV Angel](https://shizune.co/investors/profile/sv-angel) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Social Angel Investors](https://shizune.co/investors/social-angel-investors)
- [Social Angel Investors in United States](https://shizune.co/investors/social-angel-investors-united-states)
- [Social Investors in United States](https://shizune.co/investors/social-investors-united-states)

## FAQ

### What does Russell Hirsch invest in?

Russell Hirsch invests primarily in Health Care, Software and SaaS startups, most often at Seed and Pre-Seed stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Russell Hirsch last invest?

The most recent investment recorded for Russell Hirsch closed in Jun 2022. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co